STAT

3 drug pricing policy experiments to watch in 2020

States, advocates, and even the drug and insurance industries are devising novel strategies for reining in drug prices. 2020 will be the year many of those experimental ideas are tested.

WASHINGTON — Politicians spent the better part of 2019 bickering over the best way to lower drug prices. But in the meantime, states, advocates — even the drug and insurance industries — were devising novel strategies for solving this perplexing challenge.

2020 will be the year many of those experimental ideas are tested. If they pan out, they’ll undoubtedly be models for other states or companies — and perhaps serve as inspiration for Washington, too. Below, STAT

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy Insurance Coverage, Zepbound Shortages, And More
The first major U.S. health insurers have agreed to start paying for the Wegovy weight loss drug for certain people on Medicare with heart conditions.
STAT1 min read
Opinion: HHS’s Proposed Rule Pays Lip Service To Addressing The Climate Crisis, The Greatest Threat To Human Health
HHS's proposal for addressing the climate crisis serves as an example of what historian and philosopher Hannah Arendt defined as the "banality of evil."
STAT1 min read
STAT+: Pharmalittle: We’re Watching A Ban Of Compounded Versions Of GLP-1s, A Biogen Acquisition, And More
Good morning from San Diego. This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in for Ed Silverman while he’s away from the Pharmalittle campus. I’m not a coffee drinker, but who needs caffeine when you’ve got the raw adr

Related Books & Audiobooks